Market Overview

UPDATE: Jefferies Downgrades Express Scripts to Hold; Maturing Earlier

Share:
Related ESRX
Imprimis Signs Agreement With One Of Nation's Largest Pharmacy Benefit Managers; CEO Talks Disruption
A Pair Trade In U.S. Healthcare: Bullish on Centene, Neutral On Aetna

Jefferies reduced its rating on Express Scripts (NASDAQ: ESRX) from Buy to Hold and lowered its price target from $70 to $56.

Jefferies said, "We are downgrading ESRX to Hold from Buy after mgmt commented last night that 2013 Street EPS expectations (currently at 21% Y/Y growth) are overly aggressive. While we had anticipated ESRX's growth rate to decelerate after synergies from its Medco acquisition are realized, it appears that ESRX is reaching its maturity point quicker than most investors had expected."

Express Scripts closed at $27.46 on Monday.

Latest Ratings for ESRX

DateFirmActionFromTo
Nov 2016Deutsche BankUpgradesSellHold
Oct 2016UBSInitiates Coverage onNeutral
Jul 2016BarclaysMaintainsOverweight

View More Analyst Ratings for ESRX
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Downgrades Pre-Market Outlook Analyst Ratings

 

Related Articles (ESRX)

View Comments and Join the Discussion!